TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02355743
Drug: rtPA lock therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: rtPA 2 mg/2 ml, or 110% of the volume of the catheter lumen if less than 2 mL, administered locally in a volume to fill the lumen (dead space) of the CVAD, once weekly for a total of 24 weeks. rtPA will be given as research intervention as lock therapy in that it will dwell within the catheter of the CVAD for a specified duration of time and then be removed (aspirated); in this setting the medication is not given to the patient as a flush, i.e. in systemic fashion.
Study: NCT03984370
Drug: ZP4207
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abdominal SC administration
Study: NCT03701984
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: a 1,000 ml distention medium containing 5 ml serum physiologic per 250 ml and oral placebo(1 h before the procedure).
Study: NCT00353587
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: MBX-102 Placebo once daily for 16 weeks
Study: NCT00881179
Drug: Clarithromycin 250 mg Tablets (Geneva Pharmaceuticals, USA)
Normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01552590
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00734630
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lisinopril 10mg, 20mg total daily dosage, oral administration Losartan 50mg, 100mg total daily dosage, oral administration
Study: NCT02609165
Drug: rhNGF 180 µg/ml eye drops solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: eye drops
Study: NCT01032655
Drug: susceptibility test guided sequential therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: susceptibility test driven sequential therapy D1- D7 Nexium ,40mg, bid Amolin, 1gm bid D8-14 Nexium ,, 40mg, bid Flagyl, 500mg, bid~plus either one of the following~1. Klaricid, 500 mg, bid~2. Cravit, 250 mg, bid~3. Tetracycline, 500 mg, bid
Study: NCT01258634
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative Chemotherapy Courses 1 and 3: 75mg/m2; IV push day 1 Courses 2 and 4: 75mg/m2; IV push day 1, hour 0~Postoperative Chemotherapy for Good Responders Course 1: 75mg/m2; IV push day 1 Course 2: 75mg/m2; IV push day 1, hour 0~Postoperative Chemotherapy for Poor Responders Course 2: 75mg/m2; IV push day 1 Course 4: 75mg/m2; IV push day 1, hour 0
Study: NCT02711904
Drug: Extubation U
Normalized name: ADAPTER,INTUBATION CAREFUSION #1820
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose of remifentanil according to the randomization; the infusions that were used to reach the PC target were:~* 20 years old - 6.0 mcg/Kg/h~* 30 years old - 5.7 mcg/Kg/h~* 40 years old - 5.3 mcg/kg/h~* 50 years old - 5.0 mcg/kg/h~* 60 years old - 4.6 mcg/kg/h~* 70 years old - 4.3 mcg/kg/h~* 80 years old - 4.0 mcg kg/h.
Study: NCT01258634
Drug: Leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Postoperative Chemotherapy for Poor Responders Courses 1 and 3: 15 mg/m2/dose IV or PO every 6 hours, beginning 24 hours after start of methotrexate infusion and continuing until methotrexate level is \<0.1 uM
Study: NCT00328432
Drug: celecoxib 400 mg bid
Normalized name: celecoxib 400 MG
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00944047
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 60 MG/M2 every two weeks for a total of 4 cycles
Study: NCT00944047
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 600 MG/M2 every 2 weeks for 4 cycles (administered with Doxorubicin above)
Study: NCT01201057
Drug: 0.5% SPL7013 Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal gel
Study: NCT01201057
Drug: 1.0% SPL7013 Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal gel
Study: NCT01201057
Drug: 3.0% SPL7013 Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal gel
Study: NCT04123067
Drug: Placebo oral tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo daily for three subsequent days, initiated within 12h of stroke symptom onset
Study: NCT00009828
Drug: leucovorin calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00441090
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets 2.5, 5, 10 and 20 mg taken orally once daily for 28 days.
Study: NCT01121042
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: daily oral capsule matched to active study medication. Made form 100% lactose powder
Study: NCT03238300
Drug: Placebo Oral Capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: N-acetylcysteine-matched placebo tablet two pills twice daily. Participants will undergo MRI (including magnetic resonance imaging and functional MRI during an alcohol cue reactivity task) at baseline, after 10 days of N-Acetylcysteine and after 10 days of placebo.
Study: NCT03030222
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Empagliflozin matching placebo
Study: NCT04869176
Drug: Caffeine Citrate 5 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine in the form of suspension was given to the newborns.
Study: NCT04280406
Drug: Azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: azithromycin 500mg one hour before implant placement
Study: NCT04280406
Drug: Placebo oral tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: identical placebo one hour before implant placement
Study: NCT02161458
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Additionally, 30 cognitively normal adults aged 60-85 will receive a placebo; amyloid beta levels in the CSF will be measured at baseline (before drug administration) and following the full study drug (i.e., placebo) administration.
Study: NCT02624830
Drug: Sulfonylurea
Normalized name: Sulfonylurea
Approvals — FDA: no, EMA: no, PMDA: no
Description: See Arm description.
Study: NCT00286845
Drug: Standard Chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: physician determined
Study: NCT03051503
Drug: The Transdermal Therapeutic System-Fentanyl (TTS-F)
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: (TTS-F) group (n=30) 50ug/h patch, placed 12 hours preoperatively
Study: NCT02410278
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matched placebo
Study: NCT01856062
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: A placebo with similar appearance to dexamethasone will be given with a standard regimen of clomiphene citrate (100mg/day oral for 5 days) for ovulation induction
Study: NCT01315002
Drug: Placebo patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo patch
Study: NCT03228394
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo IV
Study: NCT00407888
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT00407888
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given orally
Study: NCT04058353
Drug: ELX/TEZ/IVA
Approvals — FDA: no, EMA: no, PMDA: no
Description: FDC tablet for oral administration.
Study: NCT04058353
Drug: TEZ/IVA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed-dose combination (FDC) tablet for oral administration.
Study: NCT04536272
Drug: Heparin
Normalized name: Heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administration of heparin with a target of 2-2.5 or 1.5-2.0 times baseline aPTT during ECLS.
Study: NCT04536272
Drug: LMWH
Normalized name: Low-molecular-weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of LMWH guided by weight and renal function during ECLS.
Study: NCT01423955
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo arm will receive NaCl 9mg/ml with a dose of 0.2 ml/kg. The placebo dose will be prepared prior to the surgery by a independent nurse. The calculated volume will match the volume of the active durg.
Study: NCT02889653
Drug: Any oral antithrombotics (antiplatelets or anticoagulants)
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02470546
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 1000mg twice a day
Study: NCT01760096
Drug: Glucocorticoids
Normalized name: GLUCOCORTICOIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucocorticoids0.25mg/kg every day(prednisone)
Study: NCT04102579
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: non-active dosage form
Study: NCT03419364
Drug: nicotinamide
Normalized name: Nicotinamide
DrugBank: Nicotinamide (DB02701)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2.5 gm nicotinamide given orally in 3 divided doses: 1000 mg in morning and evening, 500 mg at noon/midday
Study: NCT02406092
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide will be administered as per standard local practice.
Study: NCT02406092
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxorubicin will be administered as per standard local practice.
Study: NCT00951132
Drug: rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 10mg tablets, once daily in three months
Study: NCT00951132
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: tablet, once daily, three months
Study: NCT01218009
Drug: Placebo Spiromax
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo as a dry-powder inhaled orally using the Spiromax inhaler. During the 12-week double-blind period, participants take two (2) inhalations four times a day (QID) at approximately 7:00 AM, 12:00 PM, 5:00 PM, and bedtime.
Study: NCT03491540
Drug: Oral Gentamycin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral gentamycin:~Gentamycin 80 mg, 4 per day, on day -2 and day -1; Liquid forms in individual vials
Study: NCT04024072
Drug: Azopt 1% Ophthalmic Suspension
Normalized name: Azopt 1% Ophthalmic Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference product
Study: NCT02604615
Drug: Capecitabine(Aibin)
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: capecitabine(Aibin):625mg/m2,bid d1-5; q1w, po,5 or 10 weeks in total
Study: NCT01525602
Drug: PLX3397
Approvals — FDA: no, EMA: no, PMDA: no
Description: PLX3397 tablets, 200mg
Study: NCT03491540
Drug: Oral Placebo Gentamycin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for oral gentamycin :~Same presentation as oral gentamycin x4 per day on day -2 and day -1
Study: NCT00871689
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 60 mg/kg over 1 hour intravenously (IV) on days -7 and -6.
Study: NCT00238030
Drug: L-thryoxine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mcg/kg iv or 2 mcg/kg po at time of enrollment
Study: NCT02520219
Drug: GDP
Normalized name: GDPase
Approvals — FDA: no, EMA: no, PMDA: no
Description: GDP is a a combination therapy,repeated every 21 days. GEM(gemcitabine)1000mg/m2,ivgtt,30,d1、8; DXM(dexamethasone),40mg/d,p.o,d1-4; DDP(cis-platinum),75mg/m2,ivgtt,\>1h,d1; or DDP25 mg/m2,ivgtt,\>1h,d1-3.
Study: NCT00238030
Drug: iv thryoxine
Approvals — FDA: no, EMA: no, PMDA: no
Description: thyroxine 2 mcg/kg iv
Study: NCT02873559
Drug: testosterone
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone supplemented in 5 months
Study: NCT02878616
Drug: LFG316
Approvals — FDA: no, EMA: no, PMDA: no
Description: LFG316 single dose
Study: NCT04665154
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: single dose i.v. and s.c.
Study: NCT01291212
Drug: Testosterone and FSHr-LHr
Normalized name: testosterone and estrogen
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75U of LHr added to FSHr ovarian stimulation in IVF, when testosterone was used to improve the ovarian response
Study: NCT01291212
Drug: testosterone and FSHr alone
Normalized name: testosterone and estrogen
Approvals — FDA: no, EMA: no, PMDA: no
Description: FSHr alone used in ovarian stimulation in IVF, when testosterone was used to improve the ovarian response
Study: NCT01253213
Drug: BR55
Normalized name: Band-Aid Ourtone BR55 Bandages
Approvals — FDA: no, EMA: no, PMDA: no
Description: One to two bolus (2nd bolus optional) of BR55 per patient
Study: NCT02644590
Drug: Melatonin
Normalized name: Melatonin
DrugBank: Melatonin (DB01065)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Detailed in arm description
Study: NCT00678743
Drug: Omacor + simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Omacor 4 grams/day plus simvastatin 80 mg/day. Simvastatin dose adjusted at Investigator discretion after week 6.
Study: NCT02238288
Drug: lidocaine and epinephrine
Normalized name: epinephrine / lidocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2%
Study: NCT01344070
Drug: one of the 15 drugs listed below
Approvals — FDA: no, EMA: no, PMDA: no
Description: single, oral, immediate-release, non-combinational innovator formulation
Study: NCT01344070
Drug: one of the 15 drugs listed below
Approvals — FDA: no, EMA: no, PMDA: no
Description: single, oral, immediate-release, non-combinational generic formulation a
Study: NCT01344070
Drug: one of the 15 drugs listed below
Approvals — FDA: no, EMA: no, PMDA: no
Description: single, oral, immediate-release, non-combinational generic formulation b
Study: NCT01344070
Drug: one of the 15 drugs listed below
Approvals — FDA: no, EMA: no, PMDA: no
Description: single, oral, immediate-release, non-combinational generic formulation c
Study: NCT01533662
Drug: patients receiving saline infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: patients more than 60 years receiving 100micrograms of saline infusion
Study: NCT00879983
Drug: azithromycin (Zithromax)
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1. a single dose of azithromycin ER 2g~2. 3-day regimen of azithromycin tablet 500mg
Study: NCT01928420
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects with Alzheimer's Disease placebo comparator
Study: NCT04225793
Drug: Eziklen®
Approvals — FDA: no, EMA: no, PMDA: no
Description: The Eziclen solution should be taken in the one-time use regimen in morning before procedure.~Consumption of the full volume of the Eziklen® solution of the preparation and the additional amount of water or a clear liquid should be completed at least 2 hours and no later than 4 hours before the procedure.
Study: NCT00455143
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo given prior to surgery and continued for 24 hours postoperatively
Study: NCT00879983
Drug: azithromycin (Zithromax)
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1. 3-day regimen of azithromycin tablet 500mg~2. a single dose of azithromycin ER 2g
Study: NCT02867722
Drug: aminolevulinic acid HCl
Normalized name: aminolevulinic acid HCl
DrugBank: Aminolevulinic acid (DB00855)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Drug will be administered to consented patients
Study: NCT01376245
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: matching placebo
Study: NCT00091962
Drug: Pharmacotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recommendations to patients' PCP for medication to treat depression
Study: NCT02101229
Drug: Insulin, Asp(B28)-
Approvals — FDA: no, EMA: no, PMDA: no
Description: the insulin dose is calculated by the Diabeloop algorithm and then administered to the patient
Study: NCT02250105
Drug: ARI-3037MO
Normalized name: OVIS ARIES WHOLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lipid lowering
Study: NCT02250105
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactive
Study: NCT01143688
Drug: placebo inhaler
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00702728
Drug: isotonic saline solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive 1 ml/Kg/hr of intravenous saline solution for a minimum of 12 hours prior to catheterization. Hydration will continue to occur during the catheterization, and for a minimum of 12 hours post catheterization.
Study: NCT02820441
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01957163
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The matching placebo DPI identical in appearance to the inhaler containing active study medication.
Study: NCT03196869
Drug: induction Chrono-chemotherapy
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental group:docetaxel,cisplatin,5-FU
Study: NCT03196869
Drug: induction Routine-chemotherapy
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: control group:docetaxel,cisplatin,5-FU
Study: NCT00111670
Drug: DPP-IV Inhibitor
Normalized name: Dipeptidyl peptidase 4 (DPP-4) inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Escalating doses po bid or qd
Study: NCT00111670
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: po bid or qd
Study: NCT03687190
Drug: conventional medicine
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: participants without Tai chi training still received routine conventional medicine
Study: NCT04232514
Drug: HEC74647
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered HEC74647 200 mg orally once daily in fed state
Study: NCT04232514
Drug: HEC110114
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered HEC110114 800 mg orally once daily in fed state
Study: NCT03243006
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 tablets of placebo
Study: NCT03294330
Drug: IC-Green KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: fluorescence lymphangiography with the use of IC-Green
Study: NCT00380250
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00000520
Drug: immunoglobulins, intravenous
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00648128
Drug: Clarithromycin
Normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single-dose 500 mg immediate-release oral tablet
Study: NCT00648128
Drug: Clarithromycin
Normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: single-dose 500 mg immediate-release oral dose'
Study: NCT01262456
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02486289
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: NBMI Placebo
Study: NCT04466137
Drug: rhG-CSF/PEG-rhG-CSF
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhG-CSF 5μg/kg/day, s.c. from day 3 to day 14 or until neutrophils recover to exceed 5.0×10\^9 cells/L, whichever comes first, in the first cycle. Patient can still continue rhG-CSF 5μg/kg/day, or covert to PEG-rhG-CSF 6mg/Cycle in the following 2-4 cycle. 21 day one cycles.
Study: NCT02235246
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline will be administrated during 10 min before anesethetic induction in patients undergoing endoscopic submucosal dissection.
Study: NCT02466958
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: an inactive drug
Study: NCT03332303
Drug: Vehicle Cream
Normalized name: vehicle cream base no.160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle Cream
Study: NCT03985891
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Folfox
Study: NCT04334265
Drug: Anluohuaxian
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6g each time, twice a day
Study: NCT02782702
Drug: Botulism Toxin Treatment
Normalized name: Botulism toxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection of 50 UI of botulism toxin for treated zone
Study: NCT01919203
Drug: Remifentanil
Normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The starting dose of remifentanil is 0.5μg/kg and a step size is 0.05μg/kg. If LMA insertion is successful or failed in previous patient, an decrement or increment of 0.05μg/kg remifentanil is injected to next patient, respectively.
Study: NCT03156738
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive a single IV dose of placebo
Study: NCT01287130
Drug: AZD6244
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given orally once or twice a day depending on dose level.On days 1, 8, 15 and 22. Repeat every 28 days
Study: NCT00729209
Drug: ARRY-371797, p38 inhibitor; oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: multiple dose, single schedule
Study: NCT00729209
Drug: Placebo; oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: matching placebo
Study: NCT03865004
Drug: Dexketoprofen plus Morphine
Normalized name: dexketoprofen
DrugBank: Dexketoprofen (DB09214)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous 75 mg Dexketoprofen plus 0,1 mg/kg morphine were performed simultanously
Study: NCT01012349
Drug: Association: acetylsalicylic acid (500mg), sodium bicarbonate (1625) and citric acid (965)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 tablet in an episody of headache
Study: NCT01012349
Drug: Aspirin - Bayer
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 tablet in an episody of headache (Aspirin 500mg)
Study: NCT00122642
Drug: placebo-lock
Approvals — FDA: no, EMA: no, PMDA: no
Description: The intervention is the instillation of placebo solution in the catheter lumen (or lumina) for 15minutes per day during hospital stay and for 15minutes per week for patients not in the hospital.
Study: NCT00480701
Drug: [123I]-IBVM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will be asked to undergo an injection of 123-I IBVM followed by up to three approximately thirty minute SPECT scans during the next 24 hours.
Study: NCT03022201
Drug: Placebo DA-9701
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00307749
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: once daily for 24 weeks